Lejla Daruka

Lejla Daruka

Auto-generated profile, based on publicly available information

Lejla Daruka

Synthetic and Systems Biology Unit, Institute of Biochemistry, HUN-REN Biological Research Centre, Temesvári krt. 62, 6726, Szeged, Hungary

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
BKBálint Kintses
Bálint Kintses
PJPramod K. Jangir
Pramod K. Jangir
GFGergely Fekete
Gergely Fekete
MSMónika Számel
Mónika Számel
OMOrsolya Méhi
Orsolya Méhi
BPBalázs Papp
Balázs Papp
Antimicrobial peptides (AMPs) are key effectors of the innate immune system and promising therapeutic agents. Yet, knowledge on how to design AMPs with minimal cross-resistance to human host-defense peptides remains limited. Here, we systematically assess the resistance determinants ofEscherichia coliagainst 15 different AMPs using chemical-genetics and compare to the cross-resistance spectra of laboratory-evolved AMP-resistant strains. Although generalizations about AMP resistance are common in the literature, we find that AMPs with different physicochemical properties and cellular targets vary considerably in their resistance determinants. As a consequence, cross-resistance is prevalent only between AMPs with similar modes of action. Finally, our screen reveals several genes that shape susceptibility to membrane- and intracellular-targeting AMPs in an antagonistic manner. We anticipate that chemical-genetic approaches could inform future efforts to minimize cross-resistance between therapeutic and human host AMPs.

19 March 2015 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
APAnikó Pósa
Anikó Pósa
Renáta SzabóRenáta Szabó
Renáta Szabó
KKKrisztina Kupai
Krisztina Kupai
ACAnett Csonka
Anett Csonka
ZSZita Szalai
Zita Szalai
CVCsaba Varga
Csaba Varga
The estrogen deficiency after menopause leads to overweight or obesity, and physical exercise is one of the important modulators of this body weight gain. Female Wistar rats underwent ovariectomy surgery (OVX) or sham operation (SO). OVX and SO groups were randomized into new groups based on the voluntary physical activity (with or without running) and the type of diet for 12 weeks. Rats were fed standard chow (CTRL), high triglyceride diet (HT), or restricted diet (CR). The metabolic syndrome was assessed by measuring the body weight gain, the glucose sensitivity, and the levels of insulin, triglyceride, leptin, and aspartate aminotransferase transaminase (AST) and alanine aminotransferase (ALT). The exercise training combined with the CR resulted in improvements in the glucose tolerance and the insulin sensitivity. Plasma TG, AST, and ALT levels were significantly higher in OVX rats fed with HT but these high values were suppressed by exercise and CR. Compared to SO animals, estrogen deprivation with HT caused a significant increase in leptin level. Our data provide evidence that CR combined with voluntary physical exercise can be a very effective strategy to prevent the development of a metabolic syndrome induced by high calorie diet.

8 January 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
AMAna Martins
Ana Martins
FJFanni Judák
Fanni Judák
ZFZoltan Farkas
Zoltan Farkas
PSPetra Szili
Petra Szili
GGGábor Grézal
Gábor Grézal
CPCsaba Pál
Csaba Pál
Several antibiotic candidates are in development against Gram-positive bacterial pathogens, but their long-term utility is unclear. To investigate this issue, we studied the laboratory evolution of resistance to antibiotics that have not yet reached the market. We found that, with the exception of compound SCH79797, antibiotic resistance generally readily evolves in Staphylococcus aureus . Cross-resistance was detected between such candidates and antibiotics currently in clinical use, including vancomycin, daptomycin, and the promising antibiotic candidate teixobactin. These patterns were driven by overlapping molecular mechanisms through mutations in regulatory systems. In particular, teixobactin-resistant bacteria displayed clinically relevant multidrug resistance and retained their virulence in an invertebrate infection model, raising concerns. More generally, we demonstrate that putative resistance mutations against candidate antibiotics are already present in natural bacterial populations. Therefore, antibiotic resistance in nature may evolve readily from the selection of preexisting genetic variants. Our work highlights the importance of predicting future evolution of resistance to antibiotic candidates at an early stage of drug development.

23 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
LDLejla Daruka
Lejla Daruka
MCMárton Simon Czikkely
Márton Simon Czikkely
PSPetra Szili
Petra Szili
ZFZoltan Farkas
Zoltan Farkas
DBDávid Balogh
Dávid Balogh
AGAttila Gácser
Attila Gácser
Despite the ongoing development of new antibiotics, the future evolution of bacterial resistance may render them ineffective. We demonstrate that antibiotic candidates currently under development are as prone to resistance evolution in Gram-negative pathogens as clinically employed antibiotics. Resistance generally stems from both genomic mutations and the transfer of antibiotic resistance genes from microbiomes associated with humans, both factors carrying equal significance. The molecular mechanisms of resistance overlap with those found in commonly used antibiotics. Therefore, these mechanisms are already present in natural populations of pathogens, indicating that resistance can rapidly emerge through selection of pre-existing bacterial variants. However, certain combinations of antibiotics and bacterial strains are less prone to developing resistance, emphasizing the potential of narrow-spectrum antibacterial therapies that could remain effective. Our comprehensive framework allows for predicting future health risks associated with bacterial resistance to new antibiotics.


21 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
PSPetra Szili
Petra Szili
MCMárton Simon Czikkely
Márton Simon Czikkely
ZFZoltán Farkas
Zoltán Farkas
LDLejla Daruka
Lejla Daruka
BTBlanka Toldi
Blanka Toldi
CPCsaba Pál
Csaba Pál
Several new antibiotics target multidrug-resistant pathogens, yet resistance is still evaluated mainly by drug-susceptibility, leaving consequences for bacterial pathogenicity poorly understood. Here, we develop a framework integrating resistance evolution, genomic surveillance and host–pathogen phenotyping to classify antibiotics by resistance potential and pathogenic consequences. Applying this framework to Klebsiella pneumoniae identified functionally distinct antibiotic candidates associated with elevated virulence risk. Resistance evolution rapidly increased virulence through clinically-relevant mutations, without direct selection for pathogenicity. Despite distinct genetic routes, resistance converged on cell-envelope rewiring. A single resistance mutation increased epithelial adhesion, intracellular colonization, macrophage immune-evasion, and tissue persistence in murine infection models, transforming K. pneumoniae into a more invasive and cytotoxic pathogen. Risk-profile analysis revealed partial decoupling of resistance and pathogenicity, with some low-resistance antibiotics yielding highly-virulent populations. These findings establish resistance-driven virulence as an underappreciated translational hazard and call for incorporating host–pathogen interactions into resistance surveillance and preclinical antibiotic development.